



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



January 8, 2026

Senator Cameron Henry  
President, Louisiana Senate  
Via Email: [APA.SenatePresident@legis.la.gov](mailto:APA.SenatePresident@legis.la.gov)

**Electronic Mail – Delivery Receipt Requested**

Re: Report No. 1 of 3 for Regulatory Project 2026-04 – Institutional Pharmacy

Dear Senator Henry:

The Board of Pharmacy seeks to amend Section 1705 and repeal Sections 1715, 1717, 1719, 1721, 1723, and 1725 of its rules relative to Institutional Pharmacy. The proposed change in Section 1705 removes the restriction on the type of pharmacy permit that may be issued to a pharmacy located within an institutional facility and removes §1705.B and §1705.C regarding hospital and correctional center pharmacies which are addressed in Chapter 15 and Chapter 18 of the Board's rules. The proposed repeal of Sections 1715, 1717, 1719, 1721, 1723, and 1725 removes regulations regarding Drug Abuse Treatment Center Pharmacies that were determined to be unnecessary following the Board's review of its rules in compliance with the Governor's Executive Order No. JML 25-038 and Act 102 of the 2024 Regular Session. Drug Abuse Treatment Center Pharmacies will adhere to the remainder of Chapter 17 and Chapter 11 of the Board's rules.

In connection with this regulatory project, the following items are appended:

- Notice of Intent
- Fiscal & Economic Impact Statement

As indicated in the solicitation, we will convene a public hearing at 9:00 a.m. on Thursday, February 26, 2026 to receive public comments and testimony on the proposed changes. We will summarize those comments and our responses thereto in our next report to you. In the event you have any questions or need additional information about this project, please contact me directly at [jfontenot@pharmacy.la.gov](mailto:jfontenot@pharmacy.la.gov) or 225.925.6481.

For the Board:

M. Joseph Fontenot, Jr.  
Executive Director

cc: Chair, Senate Health & Welfare Committee  
Via Email: [APA.S-H&W@legis.la.gov](mailto:APA.S-H&W@legis.la.gov)  
Speaker, House of Representatives  
Via Email: [APA.HouseSpeaker@legis.la.gov](mailto:APA.HouseSpeaker@legis.la.gov)  
Chair, House Health & Welfare Committee  
Via Email: [APA.H-HW@legis.la.gov](mailto:APA.H-HW@legis.la.gov)  
Editor, *Louisiana Register*  
Via Email: [Reg.Submission@la.gov](mailto:Reg.Submission@la.gov)  
Reference File

**NOTICE OF INTENT**

**Department of Health**

**Board of Pharmacy**

Institutional Pharmacy (LAC 46:LIII.1705, 1715, 1717, 1719, 1721, 1723, 1725)

In accordance with the provisions of the Administrative Procedure Act (R.S. 49:950 et seq.) and the Pharmacy Practice Act (R.S. 37:1161 et seq.), the Board of Pharmacy hereby gives notice of its intent to amend §1705 and repeal §§1715, 1717, 1719, 1721, 1723, and 1725 of its rules relative to Institutional Pharmacy. The proposed change in §1705 removes the restriction on the type of pharmacy permit that may be issued to a pharmacy located within an institutional facility and removes §1705.B and §1705.C regarding hospital and correctional center pharmacies which are addressed in Chapter 15 and Chapter 18 of the Board's rules. The proposed repeal of §§1715, 1717, 1719, 1721, 1723, and 1725 removes regulations regarding Drug Abuse Treatment Center Pharmacies that were determined to be unnecessary following the Board's review of its rules in compliance with the Governor's Executive Order No. JML 25-038 and Act 102 of the 2024 Regular Session. Drug Abuse Treatment Center Pharmacies will adhere to the remainder of Chapter 17 and Chapter 11 of the Board's rules.

**Title 46**

**PROFESSIONAL AND OCCUPATIONAL STANDARDS**

**Part LIII. Pharmacists**

**Chapter 17. Institutional Pharmacy**

**Subchapter A. General Requirements**

**§1705. Institutional Pharmacy Permit**

A. ~~An~~ The board may issue an institutional pharmacy permit ~~shall be required~~ to operate a pharmacy department located within an institutional facility, other than a hospital or penal institution, for residents or patients of that institutional facility. The permit shall be applied for, and renewed, in the manner prescribed by the board in Chapter 11 of this Part.

~~B. Pharmacies operated within a hospital shall be operated in accordance with Chapter 15 of this Part.~~

~~C. Pharmacies operated within a correctional center shall be operated in accordance with Chapter 18 of this Part.~~

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2095 (October 2003), effective January 1, 2004, LR 39:313 (February 2013), amended by Department of Health, Board of Pharmacy, LR 46:584 (April 2020), amended LR

\* \* \*

**Subchapter C. Drug Abuse Treatment Center Pharmacies – Repealed**

**§1715. Purpose – Repealed**

~~A. The board may issue a pharmacy permit for a drug abuse treatment center operating in the state of Louisiana where drugs are dispensed and pharmacy primary care is provided.~~

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 29:2096 (October 2003), effective January 1, 2004, repealed LR

**§1717. Cross References – Repealed**

~~A. For all regulations that apply to drug abuse treatment center pharmacies concerning pharmacy practices not specifically stated in this subchapter, refer to Chapter 11 of this Part.~~

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 29:2096 (October 2003), effective January 1, 2004, amended by Department of Health, Board of Pharmacy, LR 46:584 (April 2020), repealed LR

### **§1719. Definitions – Repealed**

~~A. As used in this Subchapter, the following terms shall have the meaning ascribed to them in this Section:~~

~~*Administer or Administration*—the direct application of a drug to the body of a patient or research subject by injection, inhalation, ingestion, or any other means.~~

~~*Authorized Personnel*—individuals who, within the scope of their authority granted by mutual agreement of the *drug abuse treatment center's* pharmacist in charge and director, are granted access to the *drug abuse treatment center's* pharmacy department as part of his duties.~~

~~*Dispense or Dispensing*—the interpretation, evaluation, and implementation of a prescription drug order, including the preparation and delivery of a drug or device to a patient or patient's agent in a suitable container appropriately labeled for subsequent administration to, or use by, a patient. *Dispense* necessarily includes a transfer of possession of a drug or device to the patient or the patient's agent.~~

~~*Drug Abuse Treatment Center*—any establishment, facility, or institution, public or private, whether operated for profit or not, which primarily offers, or purports to offer, maintain, or operate facilities for the residential or outpatient diagnosis, care, treatment, or rehabilitation of two or more non related individuals, who are patients as defined herein, excluding, however, any hospital or mental hospital otherwise licensed by the Department of Health.~~

~~*Patient or Client*—a person who is dependent on, or otherwise suffering physically or mentally from the use of, or abuse of, controlled dangerous substances and who requires continuing care of a *drug abuse treatment center*.~~

~~*Perpetual Inventory*—a computer record of inventory kept continuously up to date by detailed entries of all incoming and outgoing items. This includes inventory on hand, purchases, and dispensing.~~

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 29:2096 (October 2003), effective January 1, 2004, amended by Department of Health, Board of Pharmacy, LR 46:584 (April 2020), repealed LR

### **§1721. Drug Abuse Treatment Center Pharmacy Permit – Repealed**

~~A. A drug abuse treatment center pharmacy permit shall be required to operate a pharmacy department located within a drug abuse treatment facility for patients of that facility. The permit shall be applied for, and renewed, in the manner prescribed by the board in Chapter 11 of this Part.~~

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 29:2097 (October 2003), effective January 1, 2004, amended by Department of Health, Board of Pharmacy, LR 46:584 (April 2020), repealed LR

### **§1723. Minimum Security Controls for Drug Abuse Treatment Centers – Repealed**

~~A. Persons enrolled in a drug abuse treatment center shall wait for their prescriptions in an area physically separated from the controlled dangerous substance (CDS) storage and dispensing area. This requirement shall be enforced by the drug abuse treatment center physician(s), pharmacist(s), and employees.~~

~~B. All CDS used in a drug abuse treatment center shall be securely locked and accessible to authorized personnel within that facility only.~~

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 29:2097 (October 2003), effective January 1, 2004, repealed LR

### **§1725. Records and Reports of Drug Abuse Treatment Centers – Repealed**

~~A. All persons licensed by the Department of Health to operate a drug abuse treatment center and who possess a Drug Enforcement Administration (DEA) registration to purchase, possess, and use CDS shall keep the following records:~~

~~1. records of CDS received by approved persons, including date of receipt, name and address of distributor, type and quantity of such drugs received, and the signature of the individual receiving the CDS. A duplicate invoice or separate itemized list furnished by the distributor will be sufficient to satisfy this record requirement, provided it includes all required information and is maintained in a separate file. In addition, duplicate copies of federal order forms for CDS listed in Schedule II must be retained; and~~

~~2. records of CDS administered or dispensed, including date of administration or dispensing, name of patient, signature of person administering or dispensing, type and quantity of drug, and such other information as may be required by state and federal laws and regulations.~~

~~B. Records of perpetual inventories shall be kept at the permitted site as prescribed by law.~~

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 29:2097 (October 2003), effective January 1, 2004, amended by Department of Health, Board of Pharmacy, LR 46:584 (April 2020), repealed LR

### **Family Impact Statement**

In accordance with Section 953 of Title 49 of the Louisiana Revised Statutes, there is hereby submitted a family impact statement on the Rule proposed for adoption, repeal, or amendment. The following statements will be published in the *Louisiana Register* with the proposed agency Rule.

1. The Effect on the Stability of the Family. The proposed Rule changes will have no effect on the stability of the family.
2. The Effect on the Authority and Rights of Parents Regarding the Education and Supervision of their Children. The proposed Rule changes will have no effect on the authority and rights of parents regarding the education and supervision of their children.
3. The Effect on the Functioning of the Family. The proposed Rule changes will have no effect on the functioning of the family.
4. The Effect on Family Earnings and Family Budget. The proposed Rule changes will have no effect on family earnings and family budget.
5. The Effect on the Behavior and Personal Responsibility of Children. The proposed Rule changes will have no effect on the behavior and personal responsibility of children.
6. The Ability of the Family or a Local Government to Perform the Function as Contained in the Proposed Rule. The proposed Rule changes will have no effect on the ability of the family or a local government to perform the activity as contained in the proposed Rule.

### **Poverty Impact Statement**

In accordance with Section 973 of Title 49 of the Louisiana Revised Statutes, there is hereby submitted a poverty impact statement on the Rule proposed for adoption, repeal, or amendment.

1. The Effect on Household Income, Assets, and Financial Security. The proposed Rule changes will have no effect on household income, assets, or financial security.
2. The Effect on Early Childhood Development and Preschool through Postsecondary Education Development. The proposed Rule changes will have no effect on early childhood development or preschool through postsecondary education development.
3. The Effect on Employment and Workforce Development. The proposed Rule changes will have no effect on employment and workforce development.
4. The Effect on Taxes and Tax Credits. The proposed Rule changes will have no effect on taxes or tax credits.
5. The Effect on Child and Dependent Care, Housing, Health Care, Nutrition, Transportation, and Utilities Assistance. The proposed Rule changes will have no effect on child and dependent care, housing, health care, nutrition, transportation, or utilities assistance.

### **Small Business Analysis**

In accordance with Section 965 of Title 49 of the Louisiana Revised Statutes, there is hereby submitted a regulatory flexibility analysis on the Rule proposed for adoption, repeal, or amendment. This will certify the agency has considered, without limitation, each of the following methods of reducing the impact of the proposed Rule on small businesses:

1. The Establishment of Less Stringent Compliance or Reporting Requirements for Small Businesses. The proposed Rule changes will have no effect on reporting requirements for small business.
2. The Establishment of Less Stringent Schedules or Deadlines for Compliance or Reporting Requirements for Small Businesses. The proposed Rule changes will have no effect on schedules or deadlines for compliance or reporting requirements for small business.
3. The Consolidation or Simplification of Compliance or Reporting Requirements for Small Businesses. The proposed Rule changes will have no effect on consolidation or simplification of compliance or reporting requirements for small business.
4. The Establishment of Performance Standards for Small Businesses to Replace Design or Operational Standards Required in the Proposed Rule. The proposed Rule changes will have no effect on establishment of performance standards for small businesses to replace design or operational standards for small business.
5. The Exemption of Small Businesses from All or Any Part of the Requirements Contained in the Proposed Rule. There are no exemptions for small businesses in the proposed Rule changes.

### **Provider Impact Statement**

In accordance with House Concurrent Resolution No. 170 of the Regular Session of the 2014 Legislature, there is hereby submitted a provider impact statement on the Rule proposed for adoption, repeal, or amendment. This will certify the agency has considered, without limitation, the following effects on the providers of services to individuals with developmental disabilities:

1. The effect on the staffing level requirements or qualifications required to provide the same level of service. The proposed Rule changes will have no effect on the staffing level requirements required to provide the same level of service.
2. The Total Direct and Indirect Effect on the Cost to the Provider to Provide the Same Level of Service. The proposed Rule changes will have no effect on the cost to the provider to provide the same level of service.
3. The Overall Effect on the Ability of the Provider to Provide the Same Level of service. The proposed Rule changes will have no impact on the ability of the provider to provide the same level of service.

### **Public Comments**

Interested persons may submit written comments, via United States Postal Service or other carrier, or in the alternative by personal delivery to M. Joseph Fontenot Jr., Executive Director, at the office of the Louisiana Board of Pharmacy, 3388 Brentwood Drive, Baton Rouge, LA 70809-1700. He is responsible for responding to inquiries regarding the proposed Rule changes. The deadline for the receipt of all written comments is 12 p.m. on Thursday, February 26, 2026.

### **Public Hearing**

A public hearing to solicit comments and testimony on the proposed Rule changes is scheduled for 9 a.m. on Thursday, February 26, 2026 at the Board office. During the hearing, all interested persons will be afforded an opportunity to submit comments and testimony, either verbally or in writing. The deadline for the receipt of all comments and testimony is 12 p.m. that same day. To request reasonable accommodations for persons with disabilities, please call the board office at 225.925.6496.

M. Joseph Fontenot Jr.  
Executive Director

## FISCAL AND ECONOMIC IMPACT STATEMENT FOR ADMINISTRATIVE RULES

### RULE TITLE: **Institutional Pharmacy**

I. ESTIMATED IMPLEMENTATION COSTS (SAVINGS) TO STATE OR LOCAL GOVERNMENTAL UNITS (Summary)

Other than the cost of rulemaking, there are no estimated implementation costs or savings for state or local government units resulting from the promulgation of the proposed Rule changes. The cost to the Louisiana Board of Pharmacy is approximately \$500 in FY 26 and \$500 in FY 27 for the notice and Rule publication in the *Louisiana Register*.

II. ESTIMATED EFFECT ON REVENUE COLLECTIONS OF STATE OR LOCAL GOVERNMENTAL UNITS (Summary)

The proposed Rule changes are not anticipated to impact the revenue collections of state or local governmental units.

III. ESTIMATED COSTS AND/OR ECONOMIC BENEFITS TO DIRECTLY AFFECTED PERSONS, SMALL BUSINESSES, OR NON-GOVERNMENTAL GROUPS (Summary)

The proposed Rule changes are not anticipated to result in significant costs or economic benefits to directly affected persons, small businesses, or non-government groups.

IV. ESTIMATED EFFECT ON COMPETITION AND EMPLOYMENT (Summary)

The proposed Rule changes are not anticipated to impact competition or employment.

**FISCAL AND ECONOMIC IMPACT STATEMENT  
FOR ADMINISTRATIVE RULES**

Person Preparing Statement:	<u>M. Joseph Fontenot, Jr. Executive Director</u>		Dept.:	<u>Dept. of Health</u>
Phone:	<u>225-925-6481</u>		Office:	<u>Board of Pharmacy</u>
Return Address:	<u>3388 Brentwood Drive</u> <u>Baton Rouge, LA 70809</u>		Rule Title:	<u>Institutional Pharmacy</u>
			Date Rule Takes Effect:	<u>Upon Promulgation July 20, 2026 (Estimated)</u>

SUMMARY  
(Use complete sentences)

In accordance with Section 961 of Title 49 of the Louisiana Revised Statutes, there is hereby submitted a fiscal and economic impact statement on the rule proposed for adoption, repeal or amendment. THE FOLLOWING STATEMENTS SUMMARIZE ATTACHED WORKSHEETS, I THROUGH IV AND WILL BE PUBLISHED IN THE LOUISIANA REGISTER WITH THE PROPOSED AGENCY RULE.

I. ESTIMATED IMPLEMENTATION COSTS (SAVINGS) TO STATE OR LOCAL GOVERNMENTAL UNITS (Summary)

Other than the cost of rulemaking, there are no estimated implementation costs or savings for state or local government units resulting from the promulgation of the proposed rule changes. The cost to the Louisiana Board of Pharmacy is approximately \$500 in FY 26 and \$500 in FY 27 for the notice and rule publication in the *Louisiana Register*.

II. ESTIMATED EFFECT ON REVENUE COLLECTIONS OF STATE OR LOCAL GOVERNMENTAL UNITS (Summary)

The proposed rule changes are not anticipated to impact the revenue collections of state or local government units.

III. ESTIMATED COSTS AND/OR ECONOMIC BENEFITS TO DIRECTLY AFFECTED PERSONS, SMALL BUSINESSES, OR NON-GOVERNMENTAL GROUPS (Summary)

The proposed rule changes are not anticipated to result in significant costs or economic benefits to directly affected persons, small businesses, or non-government groups.

IV. ESTIMATED EFFECT ON COMPETITION AND EMPLOYMENT (Summary)

The proposed rule changes are not anticipated to impact competition or employment.

**M. Joseph Fontenot, Jr.**  
Digitally signed by M. Joseph Fontenot, Jr.  
Date: 2026.01.07 12:20:54 -06'00'

Signature of Head or Designee

  
Legislative Fiscal Officer or Designee

M. Joseph Fontenot, Jr., Executive Director  
Typed Name & Title of Agency Head or Designee

January 07, 2026  
Date of Signature

1/7/26  
Date of Signature

**FISCAL AND ECONOMIC IMPACT STATEMENT  
FOR ADMINISTRATIVE RULES**

The following information is required in order to assist the Legislative Fiscal Office in its review of the fiscal and economic impact statement and to assist the appropriate legislative oversight subcommittee in its deliberation on the proposed rule.

- A. Provide a brief summary of the content of the rule (if proposed for adoption, or repeal) or a brief summary of the change in the rule (if proposed for amendment). Attach a copy of the notice of intent and a copy of the rule proposed for initial adoption or repeal (or, in the case of a rule change, copies of both the current and proposed rules with amended portions indicated).

The proposed changes in Section 1705 removes the restriction on the type of pharmacy permit that may be issued to a pharmacy located within an institutional facility and removes Subsections 1705.B and 1705.C regarding hospital and correctional center pharmacies which are addressed in Chapter 15 and Chapter 18 of the Board's rules. The proposed repeal of Sections 1715, 1717, 1719, 1721, 1723, and 1725 removes regulations regarding Drug Abuse Treatment Center Pharmacies that were determined to be unnecessary following the Board's review of its rules in compliance with the Governor's Executive Order No. JML 25-038 and Act 102 of the 2024 legislative session. Drug Abuse Treatment Center Pharmacies will adhere to the remainder of Chapter 17 and Chapter 11 of the Board's rules.

- B. Summarize the circumstances, which require this action. If the Action is required by federal regulation, attach a copy of the applicable regulation.

During the Board's review of its rules in compliance with the Governor's Executive Order No. JML 25-038 and Act 102 of the 2024 legislative session, the Board determined that there was no need for the restriction on the type of pharmacy permit issued to a pharmacy located within an institutional facility in Section 1705 and that Subsections 1705.B and 1705.C, along with Sections 1715, 1717, 1719, 1721, 1723, and 1725 were an unnecessary duplication of regulations found elsewhere.

- C. Compliance with Act 11 of the 1986 First Extraordinary Session

- (1) Will the proposed rule change result in any increase in the expenditure of funds? If so, specify amount and source of funding.

The proposed rule changes will not require any additional funding or expenditure of funds.

- (2) If the answer to (1) above is yes, has the Legislature specifically appropriated the funds necessary for the associated expenditure increase?

(a) \_\_\_\_\_ YES. If yes, attach documentation.

(b) \_\_\_\_\_ NO. If no, provide justification as to why this rule change should be published at this time

The Board of Pharmacy operates on self-generated revenue, and the Board determined the proposed repeal of these rules are in the public's best interest and is responsive to the Governor's Executive Order and Act 102.

- D. Compliance with Act 98 of the 2025 Regular Session

- (1) Will the proposed rule change result in either the expenditure of state funds or an economic impact involving costs to regulated entities estimated at \$200,000 or more per year or \$600,000 or more over three years?

(a) \_\_\_\_\_ YES. (proceed to question D.2 on this page)

(b) XX \_\_\_\_\_ NO.

- (2) If the answer to (1) above is yes, was there a fiscal note for the enacted legislation that required this action (attach documentation)?

(a) \_\_\_\_\_ YES, and all cost impacts were contemplated in the Fiscal Note.

(b) \_\_\_\_\_ YES, but cost impacts exceed those contemplated in the Fiscal Note.

(c) \_\_\_\_\_ NO.

**FISCAL AND ECONOMIC IMPACT STATEMENT  
WORKSHEET**

**I. A. COSTS OR SAVINGS TO STATE AGENCIES RESULTING FROM THE ACTION PROPOSED**

1. What is the anticipated increase (decrease) in costs to implement the proposed action?

<b>COSTS</b>	<b>FY 26</b>	<b>FY 27</b>	<b>FY 28</b>
PERSONAL SERVICES	\$0	\$0	\$0
OPERATING EXPENSES	\$500	\$500	\$0
PROFESSIONAL SERVICES	\$0	\$0	\$0
OTHER CHARGES	\$0	\$0	\$0
EQUIPMENT	\$0	\$0	\$0
MAJOR REPAIR & CONSTR.	\$0	\$0	\$0
<b>TOTAL</b>	<b>\$500</b>	<b>\$500</b>	<b>\$0</b>
<b>POSITIONS (#)</b>	<b>0</b>	<b>0</b>	<b>0</b>

2. Provide a narrative explanation of the costs or savings shown in "A. 1.", including the increase or reduction in workload or additional paperwork (number of new forms, additional documentation, etc.) anticipated as a result of the implementation of the proposed action. Describe all data, assumptions, and methods used in calculating these costs.

The estimated implementation costs for the Louisiana Board of Pharmacy are approximately \$500 in FY 26 and \$500 in FY 27 for the notice and rule publication in the Louisiana Register. There are no other estimated implementation costs or savings for state or local governmental units resulting from the promulgation of the proposed rule changes.

3. Sources of funding for implementing the proposed rule or rule change.

<b>SOURCE</b>	<b>FY 26</b>	<b>FY 27</b>	<b>FY 28</b>
STATE GENERAL FUND	\$0	\$0	\$0
AGENCY SELF-GENERATED	\$500	\$500	\$0
DEDICATED	\$0	\$0	\$0
FEDERAL FUNDS	\$0	\$0	\$0
OTHER (Specify)	\$0	\$0	\$0
<b>TOTAL</b>	<b>\$500</b>	<b>\$500</b>	<b>\$0</b>

4. Does your agency currently have sufficient funds to implement the proposed action? If not, how and when do you anticipate obtaining such funds?

The Board of Pharmacy has sufficient self-generated funds available to implement the proposed rule changes.

**B. COST OR SAVINGS TO LOCAL GOVERNMENTAL UNITS RESULTING FROM THE ACTION PROPOSED.**

1. Provide an estimate of the anticipated impact of the proposed action on local governmental units, including adjustments in workload and paperwork requirements. Describe all data, assumptions and methods used in calculating this impact.

The proposed rule changes will not result in costs or savings to local government units.

2. Indicate the sources of funding of the local governmental unit, which will be affected by these costs or savings.

The proposed rule changes will not impact sources of funding of local government units.

FISCAL AND ECONOMIC IMPACT STATEMENT  
WORKSHEET

II. EFFECT ON REVENUE COLLECTIONS OF STATE AND LOCAL GOVERNMENTAL UNITS

A. What increase (decrease) in revenues can be anticipated from the proposed action?

REVENUE INCREASE/DECREASE	FY 26	FY 27	FY 28
STATE GENERAL FUND	\$0	\$0	\$0
AGENCY SELF-GENERATED	\$0	\$0	\$0
DEDICATED	\$0	\$0	\$0
FEDERAL FUNDS	\$0	\$0	\$0
LOCAL FUNDS	\$0	\$0	\$0
<b>TOTAL</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>

\*Specify the particular fund being impacted.

B. Provide a narrative explanation of each increase or decrease in revenues shown in "A." Describe all data, assumptions, and methods used in calculating these increases or decreases.

The proposed rule changes will not affect revenue collections of state or local government units.

FISCAL AND ECONOMIC IMPACT STATEMENT  
WORKSHEET

III. COSTS AND/OR ECONOMIC BENEFITS TO DIRECTLY AFFECTED PERSONS, SMALL BUSINESSES, OR NONGOVERNMENTAL GROUPS

- A. What persons, small businesses, or non-governmental groups would be directly affected by the proposed action? For each, provide an estimate and a narrative description of any effect on costs, including workload adjustments and additional paperwork (number of new forms, additional documentation, etc.), they may have to incur as a result of the proposed action.

The proposed rule changes are not anticipated economic losses resulting from this proposed rule change.

- B. Also provide an estimate and a narrative description of any impact on receipts and/or income resulting from this rule or rule change to these groups.

The proposed rule changes will not impact a licensee's receipts or revenue.

IV. EFFECTS ON COMPETITION AND EMPLOYMENT

Identify and provide estimates of the impact of the proposed action on competition and employment in the public and private sectors. Include a summary of any data, assumptions and methods used in making these estimates.

The proposed rule changes are not anticipated to impact competition or employment.